Director, Global HEOR - Oncology at Bristol-Myers Squibb

Madison, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, OncologyIndustries

Requirements

Proficient in most, if not all, areas of evidence generation activities, including designing, conducting analysis for, and interpreting findings from interventional studies, non-interventional research, evidence synthesis studies, health economic models, and clinical outcomes assessment measures
Ability to independently lead the strategy, design, and execution of robust HEOR studies (e.g., real-world evidence, economic modeling, patient-reported outcomes studies, evidence synthesis)
Expertise as an HEOR Subject Matter Expert for oncology assets/indications supporting global markets, including the US
Strong cross-functional collaboration skills with internal stakeholders (e.g., field HEOR, Pricing & Access Strategy, Medical Affairs, Clinical Development, Marketing, PReP Team, Center of Observational Research and Data Sciences, Medical Communications/Publication Team)
Ability to lead, support, and influence internal BMS stakeholders and matrix teams
Capability to select, collaborate, and manage relationships with external organizations and Thought Leaders
Knowledge of latest global payer, HTA, health policy evolutions, and HEOR methodological developments

Responsibilities

Independently lead the strategy, design, and execution of robust evidence generation of HEOR studies (e.g., real-world evidence, economic modeling, patient-reported outcomes studies, evidence synthesis) for commercialized and pipeline oncology medicines/indications
Establish and maintain global and US cross-functional collaborative relationships with internal stakeholders including field HEOR, Pricing & Access Strategy, Medical Affairs, Clinical Development, Marketing, PReP Team, Center of Observational Research and Data Sciences, and Medical Communications/Publication Team
Support global and local market access activities, including payer and health technology assessment (HTA) submissions and negotiations, by driving comprehensive global HTA materials and helping to shape payer response strategies
Support Global Product Teams (GPT) on clinical development and regulatory activities through robust evidence generation to optimize patient access
Integrate HEOR evidence generated in-house and externally into the development of effective value communication tools and programs
Integrate evidence generation strategies in Access, Medical, and Marketing strategies and objectives
Select, collaborate, and manage relationships with external organizations and Thought Leaders for research collaborations
Keep well-informed about latest global payer, HTA, and health policy evolutions and HEOR methodological evolutions
Effectively lead and manage scientifically rigorous HEOR studies and associated budget from concept through full execution, including reporting the evidence at scientific congresses, in peer-reviewed publications, and promotional/proactive/reactive BMS communication tools
Train BMS matrix team and field teams (e.g., fHEOR, MSLs, Account Executives, sales team) on HEOR evidence as appropriate
Strive to demonstrate BMS values

Skills

HEOR

Health Economics

Outcomes Research

Oncology

Evidence Generation

Non-Interventional Studies

Health Economic Models

Clinical Outcomes Assessment

Evidence Synthesis

Value Communication

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free